profit from every $100 of sales.
$0$100
BioXcel Therapeutics
We have no price for BioXcel Therapeutics since 8 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.05-3.33% today
-93.1% in 1 year
1-year low $0.041-year high $0.70
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BioXcel Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $375,000 in 2022 to $642,000 in 2025, with -$69.9 million of profit last year.
SalesProfit
BioXcel Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioXcel Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BioXcel Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 2 | 1 | |
| 0 | 0 | 0 | 0 | |
| -160 | -168 | -65 | -50 | |
| -157 | -165 | -44 | -53 | |
| -166 | -179 | -60 | -70 | |
| -94.72 | -98.40 | -23.51 | -5.73 | |
| 94.7% | 8.7% | 5.4% | 74.5% | |
| -42,572.0% | -12,146.3% | -2,859.8% | -7,829.8% | |
| -44,201.9% | -12,974.9% | -2,630.1% | -10,887.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 206 | 74 | 38 | 45 |
| Cash | 194 | 65 | 30 | 28 |
| Total debt | 94 | 101 | 103 | 110 |
| Total liabilities | 129 | 130 | 131 | 140 |
| 77 | -57 | -93 | -95 | |
| 2 | 2 | 3 | 12 | |
| -72.9% | -294.0% | -370.9% | -294.5% | |
| -215.9% | 316.9% | 64.0% | 73.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -135 | -155 | -72 | -58 | |
| 0 | 0 | – | – | |
| -135 | -155 | -72 | -58 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 19 | 6 | 3 |
Valuation
- –
- –
- –
- -0.3×
- 3.6×
- –
- –
- -2,490.4%
- -3,021.3%
- 0.0%
Profitability
- 74.5%
- -7,829.8%
- -10,887.4%
- -9,046.2%
- -3,425.0%
- -328.8%
- 75.8%
- -221.4%
- 238.8%
- 4,160.7%
Growth
- +19.6%
- –
- +20.0%
- –
- +65.0%
Financial health
- –
- -0.95
- 294.8%
- -2.9×
- 0.62
- 0.61
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 29%of 870
What analysts expect
- Average price target
- $12.00
- Range
- $1.00 – $25.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.54 | -0.53 | −1.4% |
| Mar 26, 2026 | -0.58 | -0.34 | −70.6% |
| Nov 12, 2025 | -2.18 | -1.54 | −41.6% |
| Aug 12, 2025 | -2.45 | -2.30 | −6.5% |
| May 12, 2025 | -1.50 | -2.72 | +44.9% |
| Mar 27, 2025 | -3.57 | -4.36 | +18.1% |
| Nov 14, 2024 | -5.12 | -8.00 | +36.0% |
| Aug 6, 2024 | -3.36 | -12.16 | +72.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/5Passes 3 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
2No pass
Philip Fisher
68Pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
70Pass
Terry Smith
72Pass
Questions about BioXcel Therapeutics
Is BioXcel Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioXcel Therapeutics AI analysis
What does BioXcel Therapeutics do?
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. It is in Biotechnology.
Does BioXcel Therapeutics pay a dividend?
No. BioXcel Therapeutics does not pay a dividend at the moment.
Is BioXcel Therapeutics stock halal?
No. BioXcel Therapeutics does not pass our halal screen: its debt is 4,740% of its market value, at or above the 33% limit. How we check
How has BioXcel Therapeutics stock done over the past year?
Down 93.1% over the past twelve months, to $0.05. It traded between $0.04 and $0.70 and is 93.1% below its high.
Who are BioXcel Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BioXcel Therapeutics's.
Prices: daily closes to Oct 8, 2026. Fundamentals: company reports via invest-like data.